This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

TFS Implements Medidata Solutions’ Clinical Trial Management System To Scale Operations Across Growing Global Site Network

Stocks in this article: MDSO

European-based contract research organization (CRO) TFS has implemented Medidata CTMS™, a leading software-as-a-service (SaaS) clinical trial management system offered by Medidata Solutions (NASDAQ: MDSO), across its growing organization in an effort to scale operations of its clinical services. TFS’ recent and planned acquisitions have resulted in access to an increased and geographically expansive network of more than 900 clinical sites across Europe. TFS is leveraging Medidata CTMS to provide its growing organization with a common tool for efficiently managing and tracking site performance.

  • “Medidata CTMS’ interoperable platform enables TFS to continue providing clients with the high-quality services they have come to expect—but more efficiently and at a greater scale to meet growing customer demand,” said Tiina Nurminen, director of global clinical operations, TFS. “Having an increased network of sites means we can improve our customers’ time to patient enrollment and time to study completion, but this growth places new strains on our site management processes. By implementing Medidata CTMS across our recently expanded organization, we can harmonize our processes to best serve our customers’ trials and optimally work with sites.”

Medidata CTMS enables scalability of TFS’ client service model, seamlessly providing clients with 24/7 access to data about trial milestones. The Medidata CTMS dashboards and reports provide TFS clients with visibility into site progress—including the number of contracted sites, initiated sites and patients enrolled—so clients can make timely data-driven decisions to optimize their trials.

  • “CROs are increasingly challenged to find efficient ways of scaling their customer service offerings to meet client needs,” said Glen de Vries, president, Medidata Solutions. “The flexibility of Medidata CTMS streamlines study workflows from study start-up to site payments, helping forward-thinking TFS manage trials more efficiently for their customers.”

Connect with Medidata:

About TFS

TFS International, with headquarters in Lund, Sweden, is the largest non-listed European clinical Contract Research Organization (CRO). Clinical services are provided by four business areas; TFS Explore , TFS Develop , TFS People and TFS Academy , with annual net revenue greater than €40 million, global operations in 21 countries, and 500 employees worldwide conducting phase I, II, III, IV and non-interventional studies. Detailed information about TFS business areas, global locations and recent press releases can be obtained through its website.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs